[
  {
    "ts": null,
    "headline": "Dow Jones Futures: Nasdaq Breaks Support As Walmart Hits Milestone; AMD, Lumentum Are Earnings Movers Late",
    "summary": "Techs and chips struggled Tuesday, while consumer staples, regional banks, precious metals and industrials are areas of strength. AMD, Lumentum were earnings movers late.",
    "url": "https://finnhub.io/api/news?id=1b049f286e53edb852a0dadce172e05f33d0558acdc48c013ed9c54a4097c75f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770155691,
      "headline": "Dow Jones Futures: Nasdaq Breaks Support As Walmart Hits Milestone; AMD, Lumentum Are Earnings Movers Late",
      "id": 138347061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Techs and chips struggled Tuesday, while consumer staples, regional banks, precious metals and industrials are areas of strength. AMD, Lumentum were earnings movers late.",
      "url": "https://finnhub.io/api/news?id=1b049f286e53edb852a0dadce172e05f33d0558acdc48c013ed9c54a4097c75f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen beats Q4 expectations with 9% revenue growth, issues strong 2026 guidance",
    "summary": "Investing.com -- Amgen (NASDAQ:AMGN) reported fourth-quarter earnings that exceeded analyst expectations, with revenue climbing 9% to $9.9 billion compared to the consensus estimate of $9.46 billion. Shares were up 1.3% in after hours trading Tuesday following the announcement.",
    "url": "https://finnhub.io/api/news?id=ac8c44b24eb7e353da6c9d032606966ece5a37f6f04a84e5a31beb9758eff1be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770154900,
      "headline": "Amgen beats Q4 expectations with 9% revenue growth, issues strong 2026 guidance",
      "id": 138347224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Investing.com -- Amgen (NASDAQ:AMGN) reported fourth-quarter earnings that exceeded analyst expectations, with revenue climbing 9% to $9.9 billion compared to the consensus estimate of $9.46 billion. Shares were up 1.3% in after hours trading Tuesday following the announcement.",
      "url": "https://finnhub.io/api/news?id=ac8c44b24eb7e353da6c9d032606966ece5a37f6f04a84e5a31beb9758eff1be"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Jumps Back Into A Buy Zone After Strong Fourth-Quarter Report",
    "summary": "Amgen stock rose late Tuesday on better-than-expected fourth-quarter sales and adjusted earnings per share.",
    "url": "https://finnhub.io/api/news?id=328cba58a325d6a4ec27854e8d4a3077a8846c4a4aeb78996a48285c38bbcd66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770153560,
      "headline": "Amgen Jumps Back Into A Buy Zone After Strong Fourth-Quarter Report",
      "id": 138347225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen stock rose late Tuesday on better-than-expected fourth-quarter sales and adjusted earnings per share.",
      "url": "https://finnhub.io/api/news?id=328cba58a325d6a4ec27854e8d4a3077a8846c4a4aeb78996a48285c38bbcd66"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (NASDAQ:AMGN) Reports Upbeat Q4 CY2025",
    "summary": "Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of $37.7 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $5.29 per share was 11.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=4a7d8553f54471ba60cfbd17c8f2a2973cad32c50b90fbe5e5d0aa8e4aca3ee2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770153210,
      "headline": "Amgen (NASDAQ:AMGN) Reports Upbeat Q4 CY2025",
      "id": 138347226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of $37.7 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $5.29 per share was 11.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=4a7d8553f54471ba60cfbd17c8f2a2973cad32c50b90fbe5e5d0aa8e4aca3ee2"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Q4 Earnings Snapshot",
    "summary": "AMGN) on Tuesday reported fourth-quarter profit of $1.33 billion. On a per-share basis, the Thousand Oaks, California-based company said it had profit of $2.45. Earnings, adjusted for non-recurring costs, were $5.29 per share.",
    "url": "https://finnhub.io/api/news?id=e8be3309be5ad7f853af510b144fdb3918fd9519e824c53bd555c2c17441af17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770152837,
      "headline": "Amgen: Q4 Earnings Snapshot",
      "id": 138347227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AMGN) on Tuesday reported fourth-quarter profit of $1.33 billion. On a per-share basis, the Thousand Oaks, California-based company said it had profit of $2.45. Earnings, adjusted for non-recurring costs, were $5.29 per share.",
      "url": "https://finnhub.io/api/news?id=e8be3309be5ad7f853af510b144fdb3918fd9519e824c53bd555c2c17441af17"
    }
  },
  {
    "ts": null,
    "headline": "Amgen quarterly results beat Street estimates on higher sales, lower tax rate",
    "summary": "Feb 3 () - Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, driven by a 7% ​increase in drug sales and a lower tax rate. The California-based biotech company's ‌overall quarterly revenue rose 9% from a year earlier to $9.",
    "url": "https://finnhub.io/api/news?id=b19504f5527d73396311eb13e3199193c83c3d0eda3b79e56391fc4da49e3ee8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770152695,
      "headline": "Amgen quarterly results beat Street estimates on higher sales, lower tax rate",
      "id": 138347228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Feb 3 () - Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, driven by a 7% ​increase in drug sales and a lower tax rate. The California-based biotech company's ‌overall quarterly revenue rose 9% from a year earlier to $9.",
      "url": "https://finnhub.io/api/news?id=b19504f5527d73396311eb13e3199193c83c3d0eda3b79e56391fc4da49e3ee8"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS",
    "summary": "Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024.",
    "url": "https://finnhub.io/api/news?id=db7f91faf1ff81e970b0dda276258ee9bfb82ae8d7614af5b66fffb7db1ce762",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770152460,
      "headline": "AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS",
      "id": 138347229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024.",
      "url": "https://finnhub.io/api/news?id=db7f91faf1ff81e970b0dda276258ee9bfb82ae8d7614af5b66fffb7db1ce762"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Lawsuit Over 340B Discounts As Stock Trades Near Valuation Targets",
    "summary": "Amgen is being sued over an alleged unlawful decision to end discounted drug sales to Sagebrush Health Services under the federal 340B Drug Pricing Program. The lawsuit claims the move restricts access to lower cost medications for patients served by Sagebrush, which focuses on underserved communities. The case centers on Amgen's compliance with 340B rules that aim to reduce drug costs for vulnerable patient groups. For investors watching NasdaqGS:AMGN, this legal dispute arrives with the...",
    "url": "https://finnhub.io/api/news?id=5aac8c8dab83544502bf4aa5d9c690fe7bfda9670bc9ac015d36b782ef7e0520",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770149231,
      "headline": "Amgen Lawsuit Over 340B Discounts As Stock Trades Near Valuation Targets",
      "id": 138347230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen is being sued over an alleged unlawful decision to end discounted drug sales to Sagebrush Health Services under the federal 340B Drug Pricing Program. The lawsuit claims the move restricts access to lower cost medications for patients served by Sagebrush, which focuses on underserved communities. The case centers on Amgen's compliance with 340B rules that aim to reduce drug costs for vulnerable patient groups. For investors watching NasdaqGS:AMGN, this legal dispute arrives with the...",
      "url": "https://finnhub.io/api/news?id=5aac8c8dab83544502bf4aa5d9c690fe7bfda9670bc9ac015d36b782ef7e0520"
    }
  },
  {
    "ts": null,
    "headline": "Equities Fall Intraday as Tech Sector Slumps; Precious Metals Jump",
    "summary": "US benchmark equity indexes were lower intraday amid a plunge in the technology sector, while gold a",
    "url": "https://finnhub.io/api/news?id=c6685615e2b372c49bfe05001c6d3e1168d6a3415cbcc9529d98bf51ebe45bd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770145248,
      "headline": "Equities Fall Intraday as Tech Sector Slumps; Precious Metals Jump",
      "id": 138345459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes were lower intraday amid a plunge in the technology sector, while gold a",
      "url": "https://finnhub.io/api/news?id=c6685615e2b372c49bfe05001c6d3e1168d6a3415cbcc9529d98bf51ebe45bd2"
    }
  },
  {
    "ts": null,
    "headline": "Obesity stocks slump on Novo's underwhelming 2026 sales forecast",
    "summary": "Feb 3 (Reuters) - Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the",
    "url": "https://finnhub.io/api/news?id=2ecb05fe8802ee470a333376175f860f022e047f214bc0fafcdcd42adfc99bea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770143248,
      "headline": "Obesity stocks slump on Novo's underwhelming 2026 sales forecast",
      "id": 138345661,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Feb 3 (Reuters) - Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the",
      "url": "https://finnhub.io/api/news?id=2ecb05fe8802ee470a333376175f860f022e047f214bc0fafcdcd42adfc99bea"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline”",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks on Jim Cramer’s recent game plan. Cramer said that he heard good things about the company during the JPMorgan Healthcare Conference, as he commented: With Amgen, I don’t know if you remember, at the JPMorgan Healthcare Conference, I heard a lot of good things. The biotech really […]",
    "url": "https://finnhub.io/api/news?id=a2c2f5dd6048cb4cfbcd80a3abd03307191e6ae4915a28a09000af2c43e9e507",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121446,
      "headline": "Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline”",
      "id": 138341699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks on Jim Cramer’s recent game plan. Cramer said that he heard good things about the company during the JPMorgan Healthcare Conference, as he commented: With Amgen, I don’t know if you remember, at the JPMorgan Healthcare Conference, I heard a lot of good things. The biotech really […]",
      "url": "https://finnhub.io/api/news?id=a2c2f5dd6048cb4cfbcd80a3abd03307191e6ae4915a28a09000af2c43e9e507"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Mostly Rise Pre-Bell as Investors Await Latest Round of Corporate Earnings",
    "summary": "US equity futures were mostly pointing higher on Tuesday as traders await a fresh batch of corporate",
    "url": "https://finnhub.io/api/news?id=a4b55d3dfcdc527e15b9028fa2e3c93b8426e666df2a78822f6203e6d77b68b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770120977,
      "headline": "Stocks Mostly Rise Pre-Bell as Investors Await Latest Round of Corporate Earnings",
      "id": 138341612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "US equity futures were mostly pointing higher on Tuesday as traders await a fresh batch of corporate",
      "url": "https://finnhub.io/api/news?id=a4b55d3dfcdc527e15b9028fa2e3c93b8426e666df2a78822f6203e6d77b68b3"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Amgen (AMGN) Valuation After Ending Kyowa Kirin Rocatinlimab Collaboration",
    "summary": "Amgen (AMGN) has just walked away from its licensing and collaboration agreement with Kyowa Kirin on rocatinlimab for atopic dermatitis, a portfolio reshuffle that shifts responsibility back to Kyowa Kirin and repositions Amgen’s near term pipeline focus. See our latest analysis for Amgen. Those portfolio moves sit alongside a share price that has climbed to US$344.68, with a 30 day share price return of 5.2% and a 1 year total shareholder return of 23.14%, which suggests that momentum has...",
    "url": "https://finnhub.io/api/news?id=903ea1d34991f1cf27a78e90cd3dabfac6e69817e24fba8827063ec52a90d9a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770088476,
      "headline": "Assessing Amgen (AMGN) Valuation After Ending Kyowa Kirin Rocatinlimab Collaboration",
      "id": 138338543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has just walked away from its licensing and collaboration agreement with Kyowa Kirin on rocatinlimab for atopic dermatitis, a portfolio reshuffle that shifts responsibility back to Kyowa Kirin and repositions Amgen’s near term pipeline focus. See our latest analysis for Amgen. Those portfolio moves sit alongside a share price that has climbed to US$344.68, with a 30 day share price return of 5.2% and a 1 year total shareholder return of 23.14%, which suggests that momentum has...",
      "url": "https://finnhub.io/api/news?id=903ea1d34991f1cf27a78e90cd3dabfac6e69817e24fba8827063ec52a90d9a6"
    }
  },
  {
    "ts": null,
    "headline": "AMD earnings, Netflix-Warner Bros. hearing: What to Watch",
    "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Tuesday, February 3, including earnings results from companies like Advanced Micro Devices (AMD), Chipotle Mexican Grill (CMG), Pfizer (PFE), and Merck (MRK), and the Senate hearing on Netflix's (NFLX) proposed bid to acquire Warner Bros. Discovery (WBD). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=4ee5d7b830f8532018efe43aa21a2c2c8099f91e6a26d7cd230d9a1df55a74d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770076800,
      "headline": "AMD earnings, Netflix-Warner Bros. hearing: What to Watch",
      "id": 138337318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Tuesday, February 3, including earnings results from companies like Advanced Micro Devices (AMD), Chipotle Mexican Grill (CMG), Pfizer (PFE), and Merck (MRK), and the Senate hearing on Netflix's (NFLX) proposed bid to acquire Warner Bros. Discovery (WBD). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=4ee5d7b830f8532018efe43aa21a2c2c8099f91e6a26d7cd230d9a1df55a74d4"
    }
  }
]